Is NanoVibronix, Inc. overvalued or undervalued?

As of 15 November 2021, the valuation grade for NanoVibronix, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its investment potential. Based on the analysis, the company appears to be overvalued given its current financial metrics. The Price to Book Value stands at a mere 0.07, while the EV to EBITDA and EV to EBIT ratios are both at -1.16, reflecting significant operational challenges.
In comparison to its peers, NanoVibronix's valuation is notably worse than Nexalin Technology, Inc., which has an EV to EBITDA of -2.0124, and SINTX Technologies, Inc., with an EV to EBIT of -0.3351. The company's return metrics further highlight its struggles, with a year-to-date decline of 86.05% compared to a 2.44% gain in the S&P 500. Overall, these factors suggest that NanoVibronix is overvalued in the current market context.